Breaking News

SGS Initiates U.S. COVID-19 Clinical Trials

Phase 2/3 trial will examine the safety, tolerability, and efficacy of Sarconeos (BIO101) to treat COVID-19 related respiratory failure.

By: Contract Pharma

Contract Pharma Staff

SGS began recruiting participants in the U.S. in a multinational clinical trial of a potential drug candidate to treat COVID-19 related respiratory failure. SGS was recently selected by French biotech company Biophytis to conduct its COVA study evaluating Sarconeos (BIO101) for the treatment of COVID-19 related respiratory failure. The trial will recruit 310 participants for a maximum 28-day treatment in the Phase 2/3 trial, which will examine the drug’s safety, tolerability, and efficac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters